SHARE

Porton Pharma Solutions embark on the next frontier in Mengeš, Slovenia Porton Pharma Solutions embark on the next frontier in Mengeš, Slovenia
22.05.2024

Porton Pharma Solutions embark on the next frontier in Mengeš, Slovenia

  • Opening ceremony of the state-of-the-art research and development laboratories for active pharmaceutical ingredients, small molecules, of Porton in Mengeš

  • A donation of EUR 20,000.00 to the municipality of Mengeš for the restoration of a flooded kindergarten

  • New jobs and further growth in the field of API's small molecules in Slovenia, Mengeš
Porton Pharma Solutions embark on the next frontier in Mengeš, Slovenia

On May 22, 2024 the opening ceremony of the state-of-the-art research and development laboratories for active pharmaceutical ingredients (APIs), small molecules, of the Porton company took place in Mengeš. This marks another milestone of Porton's globalization journey after the acquisition of J-STAR Research Inc., a US based CRO, in 2017.


Porton je kot prvo tuje podjetje pripeljal v farmacevtsko industrijo koncept pogodbenih raziskav in razvoja ter proizvodnje (angl. CDMO=Contract Development and Manufacturing Organization) na področju farmacevtskih učinkovin, malih molekul. Ob tem Porton odpira nove priložnosti za rast, razvoj in inovacije, ter bo lahko zadovoljil vse večje zahteve svojih kupcev, mednarodnih farmacevtskih družb, po varnosti dobavne verige in inovativnih in zanesljivih storitvah.


The Opening ceremony was hold in the presence of Mr. Jernej Salecl, Director of General Industry, Entrepreneurship and Internationalisation Directorate at Ministry of the economy, tourism and sport, Slovenia.


"The economies of both countries are very much connected and Porton`s investment will significantly and holistically contribute to the further development of one of the most important segments of Slovenian economy - pharmaceutical industry."

Mag. Alenka Suhadolnik, Slovenia Ambasador in People's Republic of China
Porton Pharma Solutions embark on the next frontier in Mengeš, Slovenia

The initial investment of Porton totaled 50 milion Euros. Our brand renewed facilities include research and development laboratories and a Kilo Lab, featuring state-of-the-art process and analytical equipment. Porton is the first foreign company, who brought to Slovenia the real CDMO business in the field of API’s, small molecules, opening new opportunities for growth, development and innovations.


In addition to openness and reliability, dedication to innovation is the main principle of the company, which upon its arrival in Mengeš also responded to the needs of the local community and at the opening ceremony handed over a donation of EUR 20,000.00 to the municipality of Mengeš for the restoration of a flooded kindergarten.


Till now, Porton PharmaTech d.o.o., the Slovenian subsidiary of Porton Pharma Solutions Ltd., hired over 30 new employees and plans further growth. Porton has also started construction works of the pilot plant, from which in the future Porton will be able to supply its customers, well-known international pharmaceutical companies with the first batches of API's.


Porton Pharma Solutions embark on the next frontier in Mengeš, Slovenia
"Globalization is Porton's top priority strategy. For Porton, globalization means establishing R&D and manufacturing footprint in US and Europe, so as to meet our global client's increased needs on supply chain security, high quality and innovative and reliable services."

Mr. Oliver Ju, Chairman and CEO of Porton Pharma Solutions Ltd.

About Porton Pharma Solutions Ltd.

Founded in 2005, Porton Pharma Solutions Ltd. is an internationally recognized pharmaceutical contract development and manufacturing organization (CDMO) in enabling our global clients to optimize drug development and manufacturing. We provide customer development and manufacturing services for Small Molecules, TIDES, Biologics, ADCs from pre-clinical to commercial. As of December 31, 2023, we have a proven record for the delivery of more than 3000 projects and established cooperation with more than 1000 global clients.


About Porton PharmaTech, d o.o.

Porton PharmaTech d.o.o. is the European subsidiary of Porton Pharma Solutions Ltd. It is the first CDMO type of company in the pharmaceutical industry in Slovenia, dedicated to provide comprehensive services to Customers, encompassing synthesis route development, process familiarization, analytical methods development and validation and process scale-up.At Porton PharmaTech, d.o.o, Customers are fully supported by an integrated project team committed to deliver services and products within expected timelines and quality.


Disclaimer

This press release contains forward-looking statements and is not a guarantee of future results. They are given on the basis of the management's current views and assumptions regarding future events and business performance. They are subject to risks and uncertainties that include, but are not limited to, future global economic conditions, exchange rates, legal provisions, market conditions, competitor activities and other factors beyond Porton's control. If one or more such risks or uncertainties materialize, or if underlying assumptions prove incorrect, actual results could differ materially from those forecast or expected. Any forward-looking statement speaks only as of the date of the particular statement, and Porton undertakes no obligation to publicly update or correct any forward-looking statement except as required by law.

SHARE

Porton Pharma Solutions embark on the next frontier in Mengeš, Slovenia Porton Pharma Solutions embark on the next frontier in Mengeš, Slovenia
Porton Has Been Invited to the China–Slovenia Business and Investment Forum and Had a Friendly Meeting with Slovenian Officials. Porton’s New Modality Capacity Upgrade Ceremony Successfully Held Milestone | Comprehensive Enhancement of GMP Manufacturing Capacity and New Modality Service Capabilities at Porton Fengxian, Shanghai Porton Pharma Solutions Signed Strategic Partnership with Shanghai InnoStar Driving innovation and excellence in the CDMO industry, Porton Pharma Solutions 2024 CPHI Europe Review Technical Enability | Porton’s Team of Global Chemical Engineering and Technology Published Breakthrough Results in Crystal Growth & Design and reported them at the 2024 Crystal Engineering Gordon Research Conference Keep hope alive! We invite you to stay tuned to DMD Porton Experts Invited To Participate In The University Of Perugia Master PRO-API Program, Aiding In The Training Of Green Process Chemistry Professionals Porton Will Be Participating In Biotech Outsourcing Strategies Events This June Proton At CPhI North America Again Porton 2023 ESG Report Upcoming Porton Shows In Europe And The USA:Shaping Our Future Together Porton Makes Debut At DCAT Week 2024 To Jointly Promote Industry Development Join Our Founder And CEO @ DCAT Week Porton Pharma Solutions Joined The SBTi To Drive Climate Action Farewell To 2023, And WE Are Sailing Forward To 2024 The Pharma Crystallization Summit (PCS) Is Held Annually To Bring Together Developers Of New Medicines With Crystallization Challenges And The Crystallization Experts (Solution Providers) In The Industry And Academia. Porton Gets Improved In The 2023 S&P Global ESG Score Porton Pharma Solutions Announces New Flagship Facility Offering Integrated API Crystallization And Drug Product Development Services Pharma Digital Intelligence Summit Will Be Held On 5th, September, 2023 [Important Notice] Porton Announcement Regarding The Change Of Email Domain Porton Unveils Its Small Molecule Platform Headquarters In Shanghai PORTON Starts Construction Of Its Facility For Antibodies And ADCs In Shanghai Porton At DCAT Week 2023: A Highly Successful And Strategic Event Porton Released 2022 CSR Report Porton Delivers Strong 2022 Performance With 127% Sales Growth Porton Gets Above-Average S&P Global Environmental, Social, And Governance (ESG) Score
News

Insights Unveiled: Delve into Our Global News Hub!

22.05.2024

Porton Pharma Solutions embark on the next frontier in Mengeš, Slovenia

  • Opening ceremony of the state-of-the-art research and development laboratories for active pharmaceutical ingredients, small molecules, of Porton in Mengeš

  • A donation of EUR 20,000.00 to the municipality of Mengeš for the restoration of a flooded kindergarten

  • New jobs and further growth in the field of API's small molecules in Slovenia, Mengeš

Read the news

Cookie settings

Your current status

Show details